Thanks in no small part to core team member Dr. Tingjun Lei and his manufacturing team, Entopsis is now ISO certified (ISO 9001:2015 and ISO 13485:2016) to manufacture and sell medical devices.
Sarah Murray from The Financial Times wrote an article today on cancer diagnostics. Three technology platforms were discussed. The first was a breath-based technology developed by a students and researchers at MIT and Harvard Medical School. The second was Entopsis’s urine based Nutec profiling platform. And the third was a general discussion of liquid (blood) biopsies with comments by Professor Anirban Maitra from MD Anderson Cancer Center. Most current research is focused on liquid (i.e. blood) biopsies, especially in the context of detecting circulating nucleic acids or cells. Why has Entopsis chosen instead to work with urine? The strength
The Miami Herald just published an article about the relatively new healthcare startup economy in South Florida. Conventional wisdom motivates many healthcare startups to establish themselves in Boston and San Francisco. We at Entopsis are early to the game in Miami. Consider that Miami and its surrounding neighborhoods have a robust culture of disruption and improvisation. Here, being MacGyver is not a special skill. It’s a common survival trait hardwired by experience. Who has caught on to this fact? Not just smart investors like Krillion Ventures and G3 Capital but also international investors. The Floridan winds have brought hungry MacGyvers and smart capital together to create the perfect storm and we
Our dashing CFO, Dr. George Huang (see left), presents today at the CONVERGE Conference in Philadelphia! This conference is highly relevant because of the diverse representation of decision makers present, including insurers, startups, regulators, pharmaceuticals, hospital administrators and more. It’s rare to have such a broad spectrum of med tech related expertise in one place.
Entopsis is proud to support Dr. Kara Cavuoto’s research aimed at better understanding the microbiome of the pediatric eye.
The goal of our collaboration is to define the composition of the ocular surface microbial flora in children using novel culture-independent methods. Our hypothesis is that the microbiome of the ocular surface evolves with age. Additionally, we hypothesize that disruption of the normal ocular surface microbial community via antibiotics or other ocular therapies predisposes the eye to infection and disease. With the results of our pilot study, we will be able to create an ocular surface microbiome profile which would
Becton Dickinson (BD) just announced support for a few startups under the Breakout Labs program. In addition to a no-strings-attached grant, BD will provide expertise and resources where relevant to Entopsis. Ms. Lindy Fishburne from Breakout Labs commented that “Corporate partners usually wait until the end, and catch what comes out [of an accelerator program],” and that in contrast “BD is stepping in much earlier, because they understand that ‘white-space investing’ in technology is going to be critical going forward.” We at Entopsis are privileged and excited to be working with BD!
Last week was a big week for Entopsis with the raising of our seed round led by Krillion Ventures. A big Thank You to our intrepid investors for believing in our vision! We are now in a stronger position than ever to accelerate the development of specific assays based on the NuTec platform and our data analytics infrastructure. Contact us if you are a clinician or scientist and would like to explore a partnership with us to develop an assay!
If you are interested in how German works, Mark Twain’s attempt to rationalize grammatical patterns in German is an entertaining read! Thanks to DK for sending this.
Surely there is not another language that is so slipshod and systemless, and so slippery and elusive to the grasp. One is washed about in it, hither and thither, in the most helpless way; and when at last he thinks he has captured a rule which offers firm ground to take a rest on amid the general rage and turmoil of the ten parts of speech, he turns over the page and reads, “Let
United States legislation took a step into the future in 2011 by passing the FDA Food Safety Modernization Act (FSMA). The FSMA shifts the focus from a after-the-fact reactionary approach to a preventive approach. One might not expect it but the toll exacted by foodborne diseases is large. 1 in 6 people in the United States (that’s 48 million people) suffer from foodborne diseases each year. Thousands die and these deaths are needless. The shift to prevention is timely. What the FSMA does is to make food companies responsible for monitoring and preventing contamination.
Food companies will now need a